Mangoceuticals Inc

Mangoceuticals Inc(MGRX)の株式分析

$0.200

+0.009 (+4.28%)終値時点

Loading chart…
高値
0.209
始値
0.192
出来高加重平均価格
0.20
出来高
319.40K
時価総額
9.35M
安値
0.186
売買代金
63.39K
EV/EBITDA(TTM)
0.00

Mangoceuticals, Inc. is focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx and is also focused on wellness solutions. It is advancing its proprietary antiviral compound MGX-0024. The Company offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. It has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin.

www.mangorx.com

AI分析 of Mangoceuticals Inc (MGRX)

売り

Mangoceuticals Inc is not a good buy right now due to its extremely low RSI of 18.24, indicating oversold conditions, and a staggering year-to-date change of -76.56%.

バリュエーション指標

Mangoceuticals Inc(MGRX)の現在の予想PERは0.00で、5年平均は0.00です。

予想PER

大幅な割安
5年平均 P/E
0.00
現在のP/E
0.00
割高
0.00
割安
0.00

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
0.00
現在のEV/EBITDA
0.00
割高
0.00
割安
0.00

予想PSR

大幅な割安
5年平均 P/S
0.00
現在のP/S
0.00
割高
0.00
割安
0.00

Alphio AI による MGRX の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%MGRX

$1.71

シナリオ価格

基

基本

基本 · 50%MGRX

$1.48

シナリオ価格

弱

弱気

弱気 · 25%MGRX

$1.39

シナリオ価格

イベントタイムライン

2026-10-01 (ET)

16:00:00

Mangoceuticals' Former Subsidiary Secures $2.5M Investment

2026-07-30 (ET)

09:30:00

Mangoceuticals Enters Business Combination Agreement with Nuclea Energy

2026-03-17 (ET)

16:20:00

Mangoceuticals Sues Clarity Ventures for Over $73M

2026-01-13 (ET)

17:40:00

Mangoceuticals Files to Sell 2.64M Shares of Common Stock

2025-12-19 (ET)

07:40:00

Mangoceuticals Partners with Cube Group for Up to $100M Solana Digital Asset Strategy

ニュース

MGRX のよくある質問 — Alphio AI が回答

Mangoceuticals, Inc. is focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx and is also focused on wellness solutions. It is advancing its proprietary antiviral compound MGX-0024. The Company offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. It has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Mangoceuticals Inc is not a good buy right now due to its extremely low RSI of 18.24, indicating oversold conditions, and a staggering year-to-date change of -76.56%.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める